Browse Articles
Discover research articles across all indexed journals
Impact of PSMA PET staging on initial treatment in newly diagnosed prostate cancer: An emulated randomized controlled trial.
350 Background: Prostate-specific membrane antigen (PSMA) PET/CT has become a common initial staging modality for localized prostate cancer due to its increased sensitivity and specificity over conventional staging. However, the causal impact of widespread PSMA staging on initial prostate cancer treatments has not been described. Methods: We used electronic medical record data from a national, diverse health system (Veterans Health Administration) to emulate a randomized controlled trial in which patients with newly diagnosed conventionally localized unfavorable intermediate, high, and very high-risk prostate cancer were allocated to either upfront PSMA staging or conventional imaging with technetium-99 bone scan and pelvic CT or MRI. Primary outcomes included the use of any androgen deprivation therapy (ADT), advanced androgen receptor pathway inhibitors (ARPIs), radiotherapy, and radical prostatectomy assessed in the year after diagnosis. We used the cloning, censoring, and weighting technique to estimate the causal effect of PSMA staging, controlling for potential confounders. In exploratory analyses, we extracted radiographic stage from PSMA reports using a natural language processing algorithm and assessed the influence of PSMA findings (N0M0, N1M0, or M1) on treatment patterns. Results: 9,049 patients met criteria for inclusion in the emulated trial, of whom 35% underwent PSMA staging and 46% underwent bone scan. In the emulated trial, PSMA staging was associated with higher rates of any ADT usage relative to conventional staging (adjusted hazard ratio [aHR] 1.26, 95% confidence interval [CI] 1.19-1.44), higher ARPI usage (aHR 1.52, 95% CI 1.33-1.78), lower prostatectomy usage (aHR 0.69, 95% CI 0.56-0.83), and no effect on radiotherapy usage (aHR 1.10, 95% CI 0.99-1.25). Compared to patients with PSMA N0M0, ARPI usage was higher in patients with N1M0 (aHR 6.87, 95% CI 5.41-8.73) and M1 (aHR 10.13, 95% CI 8.16-1.2.58). Patients with N1M0 or M1 disease were less likely to undergo prostatectomy compared to N0M0. Similar patterns were seen in subgroup analyses within risk groups. Conclusions: In this emulated randomized trial, PSMA staging of localized prostate cancer was associated with increased rates of any ADT and ARPI use and lower rates of prostatectomy relative to conventional staging. The implications of these treatment changes on oncologic outcomes require further study.
PSMA-positive tumor vessels around renal cell carcinoma with high angiogenic potential as therapeutic targets and predictors of tumor recurrence.
561 Background: The expression of prostate-specific membrane antigen (PSMA) protein increases as prostate cancer advances and metastasizes. Recently, 68Ga-labeled PSMA PET has been used in diagnosing prostate cancer. Our previous studies demonstrated that PSMA-positive vesicles secreted by prostate cancer cells enhance the angiogenic activity of vascular endothelial cells, suggesting a role for PSMA in tumor angiogenesis. In this study, we focus on renal cell carcinoma, examining the relationship between PSMA expression in peritumoral blood vessels and clinical outcomes, particularly tumor recurrence, in surgically excised renal cancer specimens. Methods: Immunohistochemical analysis was performed on renal cell carcinoma samples from 45 patients who underwent nephrectomy or partial nephrectomy at our institution between January 2018 and December 2022. The correlation between PSMA expression levels in tumor-associated vessels and the rate of recurrence was evaluated. In addition, PSMA levels in human umbilical vein endothelial cells (HUVECs) treated with conditioned medium (CM) from renal cancer cell lines Caki1 and ACHN were analyzed by Western blotting (WB) and immunofluorescence (IF). Angiogenic activity was measured using a tube formation assay, and RNA sequencing (RNA-seq) was conducted to examine gene expression changes in endothelial cells influenced by vesicles secreted from renal cancer cells. Spatial gene expression analysis was performed to compare differences in gene expression between tumor vessels near and vessels away from the tumor. Results: Immunohistochemical staining for PSMA and CD31 revealed that only peritumoral vessels exhibited PSMA positivity. PSMA expression was categorized into three levels: weak (18 cases), moderate (11 cases), and strong (16 cases), with these levels corresponding to different recurrence rates. When the 10,000 g pellet fraction of CM from renal cancer cell lines was applied to HUVECs, they became PSMA-positive, leading to enhanced tube formation. RNA-seq analysis further demonstrated that HUVECs exposed to CM from renal cancer cells showed upregulation of pathways associated with angiogenesis. Conclusions: Vesicles secreted by renal cancer cells promote PSMA expression in vascular endothelial cells and boost angiogenic activity. Future research will aim to elucidate the mechanism by which PSMA becomes expressed in normal vascular endothelial cells, with the potential to pave the way for new anti-angiogenic therapies.
Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice.
183 Background: Radium-223 is a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and consists of up to 6 monthly injections. After the approved 6 radium-223 injections, treatment may be repeated. This study evaluated the safety and efficacy of radium-223 re-treatment in mCRPC patients in routine clinical practice. Methods: This multicenter, retrospective cohort study included patients with bone mCRPC who previously received 6 consecutive injections of radium-223 according to standard of care, and received at least one radium-223 re-treatment injection between 2014 and 2024. Patients with visceral metastases were excluded. Primary endpoint was safety (hematological and non-hematological adverse events (AEs), including skeletal-related events (SREs)). Secondary endpoints were the number of administered injections, overall survival, and alkaline phosphatase (ALP) and prostate-specific antigen (PSA) responses. Exploratory analyses intended to find variables associated with ALP response during re-treatment and completion of radium-223 re-treatment. Results: Across 7 Dutch medical centers, 61 patients were included. Median age was 75 years, 44% received prior chemotherapy, 87% previously received at least one androgen receptor pathway inhibitor and 51% received concomitant bone health agents. Median number of prior systemic therapies was 3. 81% of patients had an ECOG performance status ≥1. 95% of patients had at least one hematological AE, including 14% grade 3 hematological AEs. In total, 44 (75%) patients experienced at least one non-hematological AE during radium-223 re-treatment. No grade 4-5 AEs occurred. 11 (18%) patients developed a SRE during radium-223 re-treatment, including 2 (3%) patients with spinal cord compression. Time until first SRE was 9.5 months (95% CI, 6.2-12.8). The patients received a median number of 6 radium-223 re-treatment injections (IQR; 4-6). Overall survival was 16.9 months (95% CI, 11.9-21.9) from start of re-treatment. 56% of patients had a ≥30% ALP response and 25% had a ≥30% PSA response. Other than elevated ALP levels at baseline, no variables were associated with ≥30% ALP response during radium-223 re-treatment. High baseline hemoglobin levels, no prior chemotherapy and a PSA response ≥30% during the initial radium-223 therapy were predictors for completion of 6 radium-223 re-treatment injections. Conclusions: Radium-223 re-treatment was well tolerated and is therefore deemed safe in selected mCRPC patients. In addition, the high number of administered injections and the high ALP response rates suggest benefit in this cohort of advanced mCRPC patients. Further research should directly compare radium-223 re-treatment and other life-prolonging therapies to determine the position of radium-223 re-treatment within the therapeutic landscape of mCRPC.
Modelling protein-protein interactions for the design of vaccine chimeric antigens with protective epitopes
Ticks and tick-borne diseases are a growing burden worldwide and vaccines are effective control interventions. Vaccine formulations with tick antigens such as BM86/BM95 (BM) and Subolesin (SUB) have shown reduction in tick fitness and infestation in immunized hosts. However, antigen combination is a challenging approach to improve vaccine efficacy (E) against multiple tick species. Herein, in silico and in music algorithms were integrated to model BM-SUB protein-protein interactions to apply a quantum vaccinology approach for combining protective epitopes or immunological quantum in the chimeric antigen Q38-95. Cattle immunized with Q38-95 and infested with African blue tick Rhipicephalus decoloratus showed an 82% E similar to BM86 and higher than SUB. The immune mechanisms activated in cattle in response to vaccination with Q38-95 were mediated by anti-BM/SUB antibodies that interfered with BM-SUB interactions and through activation of other innate and adaptive immune pathways. The results support modelling protein-protein interactions affecting E to identify and combine candidate protective epitopes in chimeric antigens.
Author Correction: Cancer and One Health: tumor-bearing individuals can act as super spreaders of symbionts in communities
Quantifying the benefit of salvage radiation versus surveillance for biochemically recurrent prostate cancer after radical prostatectomy.
382 Background: The natural history of biochemical recurrence (BCR) after radical prostatectomy (RP) is heterogeneous, with most patients not progressing to metastasis. Determining the impact and optimal timing of salvage radiation therapy (SRT) remains challenging, particularly in the absence of prospective randomized trials with a surveillance control arm. Our objective isto quantify the oncologic benefit of SRT among men with BCR after RP. Methods: Patients who underwent RP at Mayo Clinic between 1990 and 2017 and developed BCR (PSA≥0.20ng/mL) were included. Patients treated with SRT were compared to those managed with surveillance using risk-set matching with time-dependent propensity scores, accounting for covariates at BCR and post-BCR. The primary outcome was metastases, analyzed via Kaplan-Meier and Cox proportional hazard models. The number needed to treat (NNT) with SRT to prevent progression was calculated using regression outputs at 5 and 15 years post-BCR. Interaction analyses identified factors modifying SRT’s effect on metastasis. Results: Of 6,881 patients with BCR, 2,109 received SRT. At a median follow-up of 10.2 years, 1,147 patients with BCR developed metastases. After 1:1 matching, SRT was associated with lower metastasis risk than surveillance at 5 years (12.7% vs 19.3%, p<0.0001) and 15 years (28.6% vs. 31.5%, p<0.001). SRT was independently associated with decreased metastasis risk (HR 0.75, 95%CI 0.63–0.90, p=0.002) on multivariable analysis, translating to NNT of 23 and 15 at 5 and 15 years, respectively (Table). Additionally, we noted a significant interaction between PSA at SRT and the association of SRT with metastasis (p-interaction=0.02), such that the reduction in metastatic progression with SRT vs. surveillance was restricted to the cohort of patients who received SRT for PSA>0.40ng/mL (HR 0.66, 95%CI 0.54–0.80, p<0.001). Conclusions: Most patients with BCR post-RP do not develop metastases. Indeed, the NNT with SRT to reduce metastasis versus surveillance indicates a generally indolent disease course. Further, the lack of a significant association of SRT with reduction of metastases in patients with a PSA≤0.40ng/mL underscores the importance of careful patient selection when considering early SRT. Our data establish the rationale for a randomized trial comparing early SRT versus surveillance for appropriately selected patients with BCR after RP. Hazard ratios of SRT after matching by propensity scores, and number needed to treat for systemic progression, prostate cancer specific mortality and overall mortality. DiseaseOutcome Hazard Ratio(95% CI) P value Number Needed to Treat* (95% CI) 5 years 15 years Systemic progression 0.75(0.63 – 0.90) 0.002 23(17 – 41) 15(11 – 27) Prostate cancer mortality 0.81 (0.64 – 1.03) 0.086 103(62 – 494) 26(15 – 124) Overall mortality 0.79 (0.70 – 0.89) 0.0001 38(29 – 62) 12(9 – 20) *Number needed to treat (NNT) calculated using regression based absolute differences in event free survival between salvage radiation therapy (SRT) and observation.
Safety and efficacy of FGFR inhibitors in urothelial carcinoma: A systematic review and meta-analysis.
782 Background: Urothelial carcinoma is the most frequently occurring bladder cancer and originates from urothelial cells lining the bladder and the urinary tract. Fibroblast growth factor receptor (FGFR) inhibitors are the emerging treatment option, due to their ability to alter FGFR signaling which plays a role in tumor proliferation, survival, and angiogenesis. This study aims to assess the efficacy of FGFR inhibitors for urothelial carcinoma. Methods: We conducted a systematic review and single-arm meta-analysis by systematically searching PubMed, Cochrane, and Embase for studies evaluating the efficacy and/or safety of FGFR inhibitors for urothelial carcinoma. The primary measures of effect were hazard ratios (HRs) and the proportion of events per 100 observations, both with 95% confidence intervals (CIs), pooled using a random-effects model with a generalized linear mixed model (GLMM). Heterogeneity was assessed using the I² statistic and Cochran’s Q test. Statistical analyses were performed using RStudio v4.3.3. Results: We included 19 studies, comprising two cohort studies and 17 clinical trials, five of which were randomized controlled trials (RCTs), with a combined total of 1,187 patients. The pooled median overall survival (mOS) was 8.77 months (95% CI, 7.28; 10.56), the pooled median progression-free survival (mPFS) was 3.46 months (95% CI, 2.73; 4.40), and the median duration of response (mDOR) was 5.38 months (95% CI, 4.72; 6.14). The grade ≥ 3 adverse effects rate was 49.43% (95% CI, 35.44; 63.51%). The overall objective response rate (ORR) was 24.16% (95% CI, 17.65; 32.14%), in the subgroup analysis of 218 patients using Erdafitinib ORR was 42.25%. The progressive disease and stable disease rates were 48.64% (95% CI, 38.88; 58.50%) and 26.07% (95% CI, 20.01; 33.21%), respectively. Conclusions: Our meta-analysis suggests that FGFR-targeted treatment regimens show promising clinical activity in urothelial carcinoma with a comparable safety profile to conventional treatment modalities.
Real-world evidence for factors associated with development of castration-resistant prostate cancer (CRPC).
92 Background: Androgen deprivation therapy (ADT) is foundational for advanced prostate cancer (PCa); luteinizing hormone-releasing hormone (LHRH) agonists and gonadotropin-releasing hormone (GnRH) antagonists are widely used. ~20% of PCa patients on LHRH analogs develop castration-resistant prostate cancer (CRPC) within 3 years. We evaluated factors associated with CRPC onset and time to CRPC onset for agonists vs. antagonist using real-world dataset. Methods: Data were collected from an EMR database purchased from Decision Resources Group. Analysis set included PCa patients who received ≥1 ADT 1991-2020 and excluded those who received both LHRH agonist and a GnRH antagonist and/or developed CRPC on the same day/before ADT initiation. CRPC onset date was defined as the earlier of 2 options: CRPC diagnosis or first CRPC therapy (standard of care treatments e.g., androgen pathway inhibitors, immunotherapy, chemotherapy, radiotherapy). Associations between CRPC and each available factor were evaluated using MV Cox regression. Time to CRPC onset was assessed for agonists vs. antagonist. Results: 41,379 patients were analyzed. Factors associated with MV HR >1.4, p<0.001 were oncology setting, metastatic disease, absence of diabetes, and no statin use (Table 1). Antagonist use had an adjusted HR of 1.4 (95% CI 1.06-1.85, p=0.02). Median time to CRPC onset after ADT initiation is 10.9 months for antagonist (n=238) vs. 17.3 months for agonists (n=5,231). Conclusions: Treatment-related (oncology setting; antagonist use) and comorbidity factors (older age, no diabetes, no statin use) were associated with CRPC onset. Oncology setting and antagonist use may reflect practice patterns in higher risk individuals. The association between diabetes and CRPC risk is under further evaluation e.g., whether antecedent diabetes therapies confer protection. Hazard ratio (95% CI) and P-value of CRPC for top 10 significant factors 1 in multivariable analysis. Multivariable (n=9,554) 2,3 Factors HR (95% CI) P-value Oncology vs Urology (Setting) 3.04 (2.56-3.59) <0.001 W vs W/o Metastasis (Baseline) 2.20 (1.58-3.05) <0.001 W/o vs W Diabetes 4 1.45 (1.22-1.73) <0.001 W/o vs W Statin 4 1.43 (1.25-1.63) <0.001 Antagonist vs Agonist 1.40 (1.06-1.85) 0.02 W/o vs W Hypertension 4 (HTN) 1.17 (1.01-1.36) 0.041 Decreasing ADT Exposure per Year 1.09 (1.05-1.13) <0.001 Increasing Age per Year (Older vs Younger) 1.02 (1.02-1.03) <0.001 1 Significant for multivariable analysis. 2 Excluded patients with CRPC on the same day/before ADT Start. 3 Excluded patients with both agonist and antagonist use; without BMI, PSA, and age data; non-white/black race; with unknown urology/oncology or with both urology/oncology setting. 4 Has taken statins/hypertension/diabetes medication or diagnosed with hypertension/diabetes disease.
Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
723 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1L maintenance therapy plus best supportive care (BSC) significantly improved overall survival (OS) and progression-free survival (PFS) vs BSC alone in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) that had not progressed with 1L platinum-based chemotherapy (PBC). In the UK, initial access to avelumab was provided via the Early Access to Medicines Scheme (EAMS) from September 2020. This study reports 24-month real-world outcomes in patients treated with avelumab 1L maintenance via the EAMS in the UK. Methods: Patients aged ≥18 years who had been diagnosed with la/mUC, demonstrated at least stable disease following 1L PBC, and initiated avelumab since October 2020 were recruited consecutively from 10 UK hospitals. Primary outcomes included real-world OS, real-world PFS, and treatment patterns by 24 months. Recruitment was completed in June 2022, and all patients had completed 24 months of follow-up from avelumab initiation by June 2024. Results: Of 106 patients recruited, 78 (73.6%) were male. Median age at diagnosis of la/mUC was 72 years. Primary tumor site was bladder in 40 (78%), and the most common metastatic sites were lymph node in 64 (60.4%), lung in 31 (33%), and bone in 20 (21.3%). ECOG performance status was 0 in 35 (33.0%),1 in 36 (34%), 2-4 in 5 (4.7%), and not recorded in 30 (28.3%). 1L PBC was carboplatin/gemcitabine in 55 (51.9%) and cisplatin/gemcitabine in 49 (46.2%). Response to 1L PBC was partial or complete response in 63 (60.0%). From avelumab initiation, median OS was 16.8 months (95% CI, 11.6-23.4) and median PFS was 8.7 months (95% CI, 7.1-14.2). Median OS from the start of 1L PBC in this population without disease progression after 1L PBC was 21.8 months (95% CI, 17.0-28.9). In subgroup analyses of patients who had received 1L carboplatin/gemcitabine or cisplatin/gemcitabine, median OS from avelumab initiation was 14.4 months (95% CI, 10.1-not estimable [NE]) and 21.4 months (95% CI, 15.4-NE), and median OS from start of 1L PBC was 19.5 months (95% CI, 14.8-NE) and 26.7 months (95% CI, 20.5-NE), respectively. Conclusions: These results provide evidence of the clinical effectiveness of avelumab 1L maintenance therapy in patients who were progression free following 1L PBC in a UK real-world setting. Median OS was shorter than previously observed in the JAVELIN Bladder 100 trial, which may be due to the worse ECOG performance status and higher proportion of patients who had received 1L carboplatin-based chemotherapy in this real-world population.
Patient perceived weight stigma and patient-centered language use preferences: A cross-sectional mixed methods analysis conducted in a large academic medical center
Background Due to the rising prevalence of obesity and its impact on healthcare, patient-specific context is needed to optimize weight management with an emphasis on reducing health care-associated weight stigma. Our survey aimed to explore institution-specific patient experiences of weight stigma and preferences for patient-centered language use regarding weight management care. Methods This cross-sectional analysis adopted a concurrent mixed methods design with a sample of individuals who opted in to complete patient experience surveys after receiving care at a large academic medical center in the United States (U.S.). Categorical and continuous variables were assessed using Chi-squared and analysis of variance. We used classical content analysis to qualitatively analyze free-text data for thematic coding. Results After a 1-week survey fielding period, 3,219 of 16,758 patients completed the survey, yielding a response rate of (19.2%) with 2,816 having available electronic health record body mass index (BMI) data. Patients were comfortable discussing weight with their primary care providers but showed variation in the preferred approach and terms. Female patients with higher BMIs reported higher rates of delayed and canceled care due to prior weight stigma (25.6% and 12.2% for patients with class 3 obesity), and preferred a slower, gentler, and less direct approach with term preferences for “healthy eating plan” and against “obesity.” Qualitative analysis yielded 27 themes grouped into three domains: Emotional Hinderances, Perceptual Hinderances, and Perceived Helpfulness. Conclusions Findings from our large single institution cohort expand on the existing weight stigma literature by identifying patient language preferences and healthcare experiences according to patient weight class and sex. Given the potential impact of understanding context-specific patient language use preferences to reduce weight stigma, we recommend other healthcare systems use a similar process to address weight stigma as part of a coordinated health system improvement initiative to enhance patient-centered weight management care.
Low-intensity pulsed ultrasound induces multifaced alterations in chromosome segregation, cytoskeletal filaments and cell junctions
How and why my company pivoted from energy to agritechnology
Grade and volume progression and its association with the Decipher genomic classifier using patients enrolled in a prospective active surveillance protocol.
262 Background: The progression of prostate cancer through serial biopsies in patients on active surveillance is a multifaceted process, with grade and volume progression offering unique perspectives on disease advancement. The Decipher genomic classifier has been recognized as a valuable tool for predicting disease progression. This study examines the relationship between the Decipher score, and other GRID signatures and pathways, and grade and volume progression in prostate cancer patients, utilizing data collected prospectively from the Miami Active Surveillance Trial (MAST). Methods: We scrutinized 224 baseline samples from 124 unique patients participating in the MAST database. Progression was categorized into grade progression, volume progression, and no progression. For patients with multiple samples, the sample with the highest Decipher score was selected. We also evaluate the association between 11 prognostic signatures, including the Decipher score and an average genomic risk score combining the 11 signatures and 20 pathways available from the Decipher GRID. Results: Out of the baseline samples, 60 demonstrated grade progression, 51 volume progression, and 113 showed no progression. We found that the Decipher was not associated to our trial definition of progression, that combined grade and volume progression however we did find a statistically significant difference in Decipher scores from patients who experience grade progression (p=0.0005) as compared to volume progression (p=0.92) when comparing them with patients with no progression. A heat map evaluating prognostic signatures and pathways available on the Decipher grid found that the majority of prognostic signatures including the Decipher score and the average risk model were more associated with grade progression compared to volume or no progression. Conclusions: Our findings suggest that the Decipher score has a stronger correlation with grade progression than volume progression in prostate cancer patients. This highlights the potential of genomic classifiers like Decipher in enhancing our understanding of disease progression and in tailoring personalized treatment strategies. Further prospective studies are required to validate these findings. Clinical trial information: NCT02242773 .
State of the genitourinary medical oncology workforce in the United States, 2024.
446 Background: There are approximately 13,400 oncologists engaged in patient care in the US as of 2022. As the field of medical oncology becomes subspecialized in not only academic but in community settings, it remains unclear unknown how many practicing oncologists identify as genitourinary medical oncologists. Methods: Using lists for the top fifty hospitals per state as ranked by US News & World Report, we identified practicing medical oncologists. We then identified those with a primary (100%) or predominant (50% or greater) areas of clinical focus in genitourinary oncology. We collected data on gender, race/ethnicity, and medical education. Results: We identified a total of total of 451 genitourinary medical oncologists in the United States. Of these, 399 (88.5%) practice in academic settings while 52 (11.5%) practice in community-based hospitals. 327 (72.5%) genitourinary medical oncologists are male, while 124 (27.5%) are female. 17 GU oncologists (3.8%) are from underrepresented minority groups in medicine. 321 oncologists (71.2%) were trained at US medical schools. 76 (16.9%) identified a particular organ (prostate, bladder, kidney, or testicle) as a clinical or research area of focus. The Northeast US had the most GU oncologists (n=150), followed by the South (n=129), West (n=97), and Midwest (n=75). Seven US states have no genitourinary medical oncologist. Conclusions: Medical oncologists with a primary or predominant focus in genitourinary cancers make up 3.4% of the medical oncology workforce in the US. Seven (14%) of US states do not have a self-identified genitourinary medical oncology expert. Gender and racial/ethnic disparities are present among the genitourinary medical oncology workforce. State of the workforce among genitourinary medical oncologists in the US. Number Male Female Underrepresented Minorities Focus Academic 399 285 114 15 Prostate (39), bladder (14), renal (18), testicular (2) Community 52 42 10 2 Renal (1), Prostate (2) Total 451 327 124 17
Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (CiPHeR).
TPS291 Background: Approximately 20-25% of patients with metastatic castration resistant prostate cancer (mCRPC) harbour a germline or somatic mutation in the homologous recombination repair (HRR) pathway genes, which are involved in the repair of double stranded DNA damage. While polyadenosine 5’diphosphoribose [poly (ADP-ribose)] polymerase inhibitors, such as olaparib and rucaparib, are effective in this subgroup, their widespread use is limited due to the associated high cost, especially in resource-constrained settings. Platinum agents like carboplatin have exquisite sensitivity to cells with defective DNA repair machinery. Carboplatin, a conventional, inexpensive chemotherapeutic agent offers a potential alternative treatment in such patients. Several retrospective small case series support this hypothesis. However, there has been no prospective study evaluating the role of carboplatin in this subset of patients. Methods: This is an Investigator-initiated, prospective phase II, single-arm clinical trial in which patients diagnosed with mCRPC harbouring HRR pathway mutations previously treated with docetaxel or novel antiandrogen agents (abiraterone, enzalutamide, apalutamide, or darolutamide) or both will be eligible. Genes involved directly or indirectly in the HRR pathway will be tested by Next Generation Sequencing (NGS).We will screen approximately 200 patients to enroll 49 patients, and carboplatin (dosing at the area under curve=5) will be administered every 3 weeks until progression or intolerable side effects. The primary endpoint will be assessed as the proportion of patients with a reduction of serum prostate-specific antigen by more than 50% from enrolment. Using Simon’s two-stage design, 24 patients will be enrolled initially in the first stage. If at least 6 or more patients achieve a response, the trial will continue until enrolment of a total of 49 patients. Secondary outcomes include progression-free survival—soft-tissue disease progression (by response evaluation criteria in solid tumours, version 1.1, and bone lesion progression using Prostate Cancer Clinical Trials Working Group 3 criteria), health-related quality of life during carboplatin treatment using the Functional Assessment of Cancer Therapy—Prostate questionnaire and the European Organisation for Research and Treatment of Cancer questionnaire and safety profile of carboplatin (National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0). The trial started enrolment in September 2023. The prespecified activity goal for the first stage of accrual was met; the second stage of accrual began in July 2024. This trial is ongoing and 30 patients have been recruited to date. All 49 participants will be enrolled according to plan. Clinical trial information: CTRI/2023/04/051507 .
LuCarbo: A phase 1a/1b trial of <sup>177</sup> Lu-PSMA-617 (LuPSMA) with carboplatin in advanced prostate cancer.
TPS304 Background: LuPSMA is a proven life-prolonging therapy in men with metastatic castrate-resistant prostate cancer (mCRPC) who have previously received a taxane and an androgen receptor pathway inhibitor (ARPI). Despite patient selection by PSMA-PET/CT, responses are only seen in 50% of patients with PSMA-avid disease and are generally not durable. The mechanism of LuPSMA relies on delivery of beta emissions upon target engagement, thereby leading to DNA damage. Carboplatin is an inexpensive and widely available agent used as a radiosensitizer in other solid tumors and often combined with a taxane in CRPC. Given the need to improve outcomes with LuPSMA and the mechanisms of action of both agents, there is a rationale to evaluate the combination of LuPSMA with carboplatin in mCRPC. Methods: This is a single-center phase 1a/1b trial of LuPSMA and carboplatin. Patients with mCRPC who have previously received ≥1 taxane and ≥1 ARPI and have PSMA-avid disease on baseline PSMA-PET/CT are eligible. LuPSMA is given at the standard dose of 7.4GBq every 6 weeks, and carboplatin is dosed every 3 weeks, with 6 weeks constituting 1 cycle. In phase 1a, a 3+3 design is used with 3 planned dose levels of carboplatin (DL1 – AUC2; DL2 – AUC3: DL3 – AUC4); the dose-limiting toxicity (DLT) period is during cycle 1, and the recommended phase 2 dose (RP2D) will be the highest administered dose level with ≤1 DLTs out of 6 treated patients. In phase 1b, 19 patients will be enrolled at the RP2D (for a total of 25 patients treated at RP2D), and these patients will additionally undergo baseline and on-therapy research biopsies and an on-therapy PSMA-PET/CT after 2 cycles. The primary objective is to evaluate the safety of the combination and establish the RP2D; secondary objectives include overall response rate (PSA50 – reduction in PSA by ≥50% - and objective response rate, per RECIST 1.1), radiographic progression-free survival (per RECIST 1.1/PCWG3) and overall survival. Exploratory objectives include evaluation of genomic, transcriptomic, proteomic, and imaging biomarkers of response and resistance. With a sample size of 25 patients treated at RP2D, the combination will be deemed effective if 15 or more PSA50 responses are seen; the probability of concluding that the combination is effective is ≤0.1 if its true PSA50 rate is ≤45% and ≥0.9 if the true PSA50 rate is ≥70%. The study was activated in May 2024, and a total of 6 patients have been enrolled to date. Clinical trial information: NCT06303713 .
The recombinant spike S1 protein induces injury and inflammation in co-cultures of human alveolar epithelial cells and macrophages
The current lack of a straightforward and convenient modeling approach to simulate the onset of acute lung injury (ALI) has impeded fundamental research and hindered the screening of therapeutic drugs in coronavirus disease 2019 (COVID-19). The co-cultured human pulmonary alveolar epithelial cells (HPAEpics) and alveolar macrophages (AMs) were exposed to the complete medium, three concentrations of recombinant spike S1 protein (0.1, 1, and 10 μg/mL), or lipopolysaccharide (LPS) (10 μg/mL). The cells were harvested at 1, 2, and 3 days post-exposure. Lactate dehydrogenase (LDH) release, and IL-6, TNF-ɑ, and malondialdehyde (MDA) production were quantified and compared. Compared to those exposed to medium, co-cultures of HPAEpics and AMs exposed to a concentration of S1 protein at 10 μg/mL demonstrated significantly increased levels of LDH release (22.9% vs. 9.1%, and 25.7%), IL-6 (129 vs. 74, and 110 pg/mg of protein), and TNF-ɑ (75 vs. 51, and 86 pg/mg of protein) production, and similar to those exposed to LPS. However, no statistically significant differences were observed in MDA production. Compared to those harvested at 1 or 2 days post-exposure, co-cultured cells harvested at 3 days post-exposure exhibited increased levels of LDH release (23.4% vs. 14.9%, or 16.7%), IL-6 (127 vs. 81, or 97 pg/mg of protein) and MDA (5.6 vs. 3.2, or 3.8 nmol/mg of protein) production, but exhibited lower TNF-ɑ (58 vs. 79 pg/mg of protein) production than those harvested at 2 days post-exposure. After 3 days of exposure, co-cultures of HPAEpics and AMs showed significantly increased levels of LDH release (25.3% vs. 18.4%), and MDA production (5.5 vs. 4.3 nmol/mg of protein) compared to HPAEpics monocultures, and increased levels of LDH release (25.3% vs. 13.8%), IL-6 (139 vs. 98 pg/mg of protein) and MDA (5.5 vs. 4.7 nmol/mg of protein) production, and decreased TNF-ɑ (59 vs. 95 pg/mg of protein) production compared to AMs monocultures. Conclusions: The exposure to a concentration of S1 protein at 10 μg/mL in co-cultures of HPAEpics and AMs induced significant injury and inflammation three days post-exposure. This methodology for establishing a COVID-19-associated ALI model may have promising potential applications and value.
Variations of autonomic arousal mediate the reportability of mind blanking occurrences
Missed opportunity: PROMs as primary endpoints in bladder cancer trials.
682 Background: Bladder cancer is the sixth most common malignancy in the United States. Recent advances in treatment paradigm have changed the landscape of bladder cancer. Patient-reported outcome measures (PROMs) are measures of symptom burden and health related quality of life (HRQoL) that come directly from the patient, without clinician interpretation. PROMs can be the intervention and/or the outcome in a trial. We aimed to evaluate the trends in the usage of PROs for patients with muscle invasive bladder cancer (MIBC) and locally advanced or metastatic bladder (mBC) cancer as a measure of endpoints across global clinical trial databases. Methods: We searched the clinicaltrials.gov database for phase III trials involving muscle invasive, locally advanced and metastatic bladder cancer patients from 1990 to 2024. The data extraction included primary and secondary endpoints, PROMs, PRO parameters, and clinical trial duration. Descriptive statistics derived were used to summarize the data. Results: Fifty-four trials were included in the analysis, out of which 64.8% (n=35) were for mBC and 35.1% (n=19) for MIBC. Twenty-nine trials (53.7%) included PROMs as endpoint measures, more than half in MIBC (n=16, 55%). Approximately one third (n=13/35) of mBC included PROMs in their trials (37.1%) whereas (84.2%) included PROMs in MIBC trials (n= 16/19). None of the studies reported PROs as a primary outcome measure, twenty-three studies (79%) reported PROs as a secondary outcome, and only one (3.4%) reporting it as both primary and secondary outcome measure. In mBC nine trials (56.25%) in the 1 st line setting, six studies (37.5%) in the 2 nd line setting and one trial (6.25%) labelled as adjuvant after radiation. In MIBC trials, three studies (23%) were in the adjuvant setting, five studies (38%) in the neoadjuvant setting and one trial (8%) involving both adjuvant & neoadjuvant, and four studies (31%) in the chemoradiotherapy setting. Eleven different symptom domains were utilized to measure PROs across both the groups. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C30) and the EuroQOL 5-dimension 5-level Questionnaire (EQ-5D-5L) were the most frequently utilized PRO scales, being used in 62.5% and 37.5% of PRO reporting studies respectively. Conclusions: PROMs are increasingly used in bladder cancer trials, especially for MIBC. Approximately one-third of the trials included PROMs, yet none utilized them as primary endpoints, indicating a missed opportunity to truly understand treatment impact from the patient's perspective. Future research should prioritize PROMs as primary outcome measures to ensure patient-centered care and improve quality of life for bladder cancer patients. Further efforts are needed to standardize the current available scales to measure PROs.
Clinical protocols to monitor efficacy of [ <sup>177</sup> Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
39 Background: To assess the prognostic value of post-therapy [ 177 Lu]Lu-PSMA (LuPSMA)-SPECT/CT by visual RECIP 1.0 during LuPSMA radioligand therapy and to develop an evidence-based clinical protocol to monitor efficacy to LuPSMA. Methods: Patients who received LuPSMA between April 2019 and November 2023 and who underwent at least two LuPSMA-SPECT/CT (SPECT) were included. Three independent readers interpreted pairs of baseline and interim LuPSMA-SPECT/CT after 2 cycles of therapy for visual Response Evaluation Criteria In PSMA-imaging (RECIP) 1.0. The primary outcome was the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival after LuPSMA. The secondary outcome was the agreement between SPECT and PSMA-PET/CT (PET) performed after 2 cycles of LuPSMA. Results: 105 patients were included. In SPECT PD was associated with shorter OS compared to SD (HR=2.51;95%;CI:1.19-5.28;p=0.015) and to PR (HR=6.48;95%;CI:2.67-15.70;p<0.001). 73/105 (69.5%) had a PET after 2 cycles. 7/73 (10%), 30/73 41%), 22/73 (30%), and 30/73 (41%) patients had a tumor progression by SPECT, PET, SPECT+PSA, and PET+PSA, respectively. All 7/73 (10%) patients with PD by SPECT had PD by PET. The C-index for SPECT was inferior to the one of SPECT+PSA (0.54 vs 0.62; p=0.03) and PET (0.54 vs 0.66; p<0.001) while SPECT+PSA did not differ significantly from PET (0.62 vs 0.66; p=0.07). Conclusions: Post-therapeutic SPECT/CT by RECIP 1.0 after 2 cycles of LuPSMA therapy is prognostic for overall survival and can be used for treatment response evaluation purposes. PSMA-PET/CT identified significantly higher number of patients with progressive disease compared to LuPSMA-SPECT/CT. A composite classification system of LuPSMA-SPECT/CT+PSA was not significantly different from interim PSMA-PET/CT for response evaluation to LuPSMA.